Diligence memo · auto-generated · as of July 2, 2026
EnteroBiotix LTD
EnteroBiotix LTD looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
EnteroBiotix LTD operates in Biotechnology, based in GLASGOW.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
EnteroBiotix LTD has raised $23M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $11M on 2022-08-30.
Most recent recorded round closed around 2025-07-11.
Valuation (modeled)modeled
Provath models EnteroBiotix LTD at approximately $4.4M (range $1.5M–$7.6M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.28× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 12 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 1.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 70% of Biotechnology peers (4293 compared).
Modeled value ranks above 9% of those peers.
Closest niche peers: Acasti Pharma Inc., Edesa Biotech, Inc., 4DMedical Ltd, Arialys Therapeutics, Inc., Nuclein, LLC.
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.